SAREPTA THERAPEUTICS INC
SRPTNASDAQ🏆 #1532 by market capUS Equity
$18.23▲ $1.10 (+6.05%)
Live1h—
24h▲ 6.0%
7d▲ 11.2%
14d▲ 18.0%
30d▼ 3.9%
1y▲ 1.6%
🏦Market Cap
$1.92B
Small Cap
📈Revenue Growth (YoY)
-20.4%
Declining
📊Gross Margin
67.5%
High
💵FCF Margin
16.4%
Healthy
⚖️P/S Ratio
0.9x
Cheap
Otter Score
64
Fair
Trading Snapshot
- Day Range
- $18.15 – $18.59
- 52-Week Range
- $14.68 – $25.32
- Volume
- $3.96B
- Avg Volume
- $4.72B
- Shares Outstanding
- 105.6M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.06B
- Last Q Revenue
- $528M
- P/E Ratio
- —
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-1.82
- Dividend Yield
- —
Why Investors Own SRPT
- ✓High-growth profile — revenue up -1.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2.06B▲ +1.4% YoY
Gross Margin (TTM)
74.3%▲ +0.4% YoY
Operating Income (TTM)
$444M▲ +1.4% YoY
Free Cash Flow (TTM)
$404M▲ +1.4% YoY
About SAREPTA THERAPEUTICS INC
A company profile for SAREPTA THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
64/100
Analyst Price Target
ⓘAverage Target
$18.62
▲ +2.1% Upside
High Target$22.95
Low Target$14.94
Based on 27 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
SAREPTA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift SRPT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
SAREPTA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.